Evidence for body weight management Strong focus on obesity-related complications New liver disease evidence emerges Mechanism-informed care Read the publication: #ECO2026 To view or add a comment, sign in EASO Publication Spotlight The updated EASO framework helps clinicians match pharmacological obesity management to an individuals health needs, moving beyond weight loss alone to consider complications, mechanisms and treatment goals
Not yet FDA-approved
Everyones body and skin are different, so the number of treatments you may need can vary
GLP-1 drugs, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), act in various ways - they slow gastric emptying, curb appetite, and enhance insulin secretion
We ensure this is the right path for you and adjust your plan based on your unique response
How does human growth hormone therapy in Massachusetts support hormone optimization